Validation of the European renal best practice guideline algorithm for management of older patients with advanced chronic kidney disease : a commentary by Farrington, Ken et al.
Validation of the European Renal Best Practice guideline
algorithm for management of older patients with advanced
chronic kidney disease: a commentary
Ken Farrington1,2, Maarten Taal3,4 andWim Van Biesen 5
1Renal Unit, Lister Hospital, Stevenage, UK, 2Centre for Health Services and Clinical Research, University of Hertfordshire, Hatfield, UK,
3Department of Renal Medicine, Royal Derby Hospital, Derby, UK, 4Division of Medical Sciences and Graduate Entry Medicine, University of
Nottingham, Nottingham, UK and 5Renal Division, Ghent University Hospital, Ghent, Belgium
Correspondence to: Ken Farrington; E-mail: ken.farrington@nhs.net
The global population is ageing. In 2015, 900 million people
were 60 years of age (12.3% of the population) and by 2050
this number is predicted to rise to 2.1 billion or 21.3% of the
population [1]. This increase in life expectancy is most encour-
aging, but also presents significant challenges. Older age is ac-
companied by a high prevalence of long-term medical
conditions, disability, frailty and dependency, all of which can
impair the quality of life of both patients and caregivrs and im-
pact on health and social services [2, 3]. In parallel with all
these, the global prevalence of chronic kidney disease (CKD) in
older people is also high [4] and these patients experience high
levels of comorbidity, frailty and physical and cognitive dys-
function [5, 6].
Although the prevalence of CKD Stages 3 and 4 is high in
older people, the rate of progression of the condition tends to
be slow [7–9]. Moreover, the high mortality rate in these
patients, particularly related to cardiovascular causes, tends to
pre-empt the development of end-stage kidney disease (ESKD)
in a high proportion of patients [8]. This is starkly illustrated by
the findings of a large registry study [10] in which the prevailing
estimated glomerular filtration rate (eGFR) level, below which
the risk of ESKD exceeded the risk of death, was 15mL/min/
1.73m2 for persons 65–84 years old, while in older patients, the
risk of death always exceeded that of ESKD. These findings pre-
sent a number of dilemmas in relation to the management of
advanced CKD in older patients. The dominant concerns in
this setting revolve around shared decision making with respect
to referral for consideration of renal replacement therapy
(RRT) and in relation to the choice of RRT and conservative
management [11]. The importance of shared decision making
is universally accepted, but patients’ narratives suggest that it is
poorly implemented in this setting [12]. The recent European
Renal Best Practice (ERBP) Clinical Practice Guideline on man-
agement of older patients with advanced CKD addresses these
issues [13].
Figure 1 depicts an algorithm outlining the management
pathway for older patients with advanced CKD (eGFR
<45mL/min/1.73m2), which was proposed in the ERBP guide-
line. The purpose of the algorithm was to generate information
to guide shared decision-making discussions with patients and
their caregivrs. The main elements of the algorithm comprise
(i) establishing the risks of mortality within the next 5 (and 2)
years using a validated equation [14]; (ii) establishing the risks
of progression to ESKD in the next 1, 2 and 5 years using the
validated Kidney Failure Risk Equation (KFRE) [15]; (iii) for
patients whose mortality is judged to be very high on the basis
of their Bansal score, and/or a high level of frailty as indicated
by a validated method and who have a lower risk of developing
ESKD as judged by their Tangri score, management recommen-
dations should reasonably be focused on preparations for sup-
portive/palliative care rather than referral for discussions about
RRT; (iv) for patients whose scores indicate a low risk of pro-
gression to ESKD (and whose mortality risk is relatively low),
management recommendations should focus on preservation
of residual kidney function rather than referral for discussions
about RRT; and (v) for those whose scores indicate a high risk
of progression to end-stage renal disease (ESRD), management
recommendations should include referral for discussion about
the choice of preparation for RRT or conservative management.
Mortality risk as indicated by the Bansal score should inform
these discussions. For patients whose eGFR is <15mL/min/
1.73m2, use of the validated French national Renal
Epidemiology and Information Network (REIN) registry study
equation [16], which predicts 6-month mortality following dial-
ysis initiation, could also provide useful information. It should
be emphasized that the ERBP algorithm does not stipulate abso-
lute values of risk. Individual patients have different thresholds
for the attribution of ‘high’ risk. These relate to their particular
circumstances and inform their treatment preferences, which
are an important input into shared decision-making
discussions.
A recent publication has attempted to validate major aspects
of this algorithm [17] in a subset of patients from the
Norwegian Nord-Trøndelag Health Study (HUNT) study. The
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study cohort consisted of 1188 patients, 65 years of age, all of
whom had an eGFR <45mL/min/1.73m2. The follow-up pe-
riod was 5 years. Since the Bansal and KFRE equations were de-
veloped and validated in different study populations, it is not
known whether they are well calibrated in the same study popu-
lation. Hence the study sought to validate the performance of
each equation in this setting and to evaluate their concurrent
use in this cohort to determine how risk of death and ESRD are
compared. An additional aim was to assess, using decision
curve analysis (DCA), the clinical impact of this referral algo-
rithm compared with algorithms from other guidelines across a
range of possible patient valuations of risk and benefits [18].
Rigorous evaluation of guideline flowcharts is rare, so the
authors should be heartily congratulated for having conducted
this very relevant exercise.
The findings demonstrated good overall agreement between
actual and predicted endpoints for both equations. Of note, and
maybe for some strikingly, only 42 of the 1188 patients (3.5%)
actually progressed to ESKD over the 5-year observation period.
Based on the KFRE, this was predicted to be 4.9%. In stark con-
trast, mortality over the 5-year follow-up period was 10-fold
higher, with 462 patients (38.9%) dying versus a predicted mor-
tality of 30.1% based on the Bansal equation. Both equations
thus appeared well calibrated in this cohort, although some
non-linearity of the observed versus predicted mortality slope
implied some slight underestimation of mortality by the Bansal
equation at lower risk levels. The ability to discriminate between
patients progressing to ESRD and those not was excellent (C-
statistic 0.93), while the accuracy of death prediction was mod-
erate (C-statistic 0.71).
Concurrent application of the prediction equations in the al-
gorithm demonstrated that while only 31 patients had a risk of
progressing to ESKD over a 5-year period greater than their risk
of death over the same period, the majority [19 (61%)] of these
actually did progress to ESKD during that time, while 5 (16%)
died during follow-up and 7 (23%) experienced neither event.
The important baseline characteristics that discriminated be-
tween progression to ESKD, death and event-free survival over
the follow-up period included age, eGFR and health status.
When these factors were examined in the study population, a
number of findings emerged. In the very elderly patients
(80 years), only 2 of 598 (0.3%) progressed to ESKD in the
next 5 years. Progression to ESKD was much less frequent than
death at all levels of baseline eGFR except <15mL/min/
1.73m2, which is in keeping with the findings of previous stud-
ies [8, 10]. Low levels of self-reported health at baseline were as-
sociated with death during follow-up, although a large
proportion of patients who progressed to ESKD were also in
this category.
While these findings provide welcome support for the po-
tential utility of the ERBP-proposed algorithm in facilitating the
management of older patients with advanced kidney disease,
some methodological issues should be considered. As in most
registries, there is an assumption that the number progressing
to ESKD is equivalent to the number actually starting on RRT.
The underlying reason for this is that there is no specific
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FIGURE 1: Decision flow chart to guide shared decision making when managing older patients with CKD of Stage 3b or worse (eGFR
<45mL/min/1.73m2) based on estimation of mortality risk using the Bansal score [14] and risk of progression to ESKD based on the score
generated by the KFRE [15]. For patients with eGFR <15mL/min/1.73m2, the REIN score [16] provides a risk prediction of death in the first
6months after dialysis initiation.
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definition for ‘ESKD’ other than the start of RRT. As a conse-
quence, there is no option to capture patients with CKD Class 5
but not on dialysis. Most regional and national registries also
lack the option to register this group of conservatively managed
patients with ESKD. Hence it is not possible to identify the pro-
portion of patients who would otherwise have started on RRT
but may have opted for conservative management. Some of
these would have died and others would still be alive but not re-
ceiving RRT. The authors acknowledge this limitation and
quote Norwegian registry data that suggest 7–16% of patients
opt for conservative management. Another issue is the chal-
lenge of defining frailty. Using the data available in the HUNT
study, only 7.2% of the study cohort was designated as frail,
whereas published figures for a population at dialysis initiation
report up to 73% [19].
It is axiomatic that the ERBP algorithm does not define
thresholds above which the risk is designated as high since
thresholds will vary greatly between individuals according to
their circumstances and preferences. Hallan et al. [17] tackle
this issue using DCA [18], applied within the study cohort, to
examine the clinical utility of the ERBP and other referral algo-
rithms across a hypothetical range of patients’ valuation of
harm versus benefit. Benefit is defined as the timely referral for
preparation for RRT in those who progress to ESKD as their
first event, harm as the same referral in those who die as their
first event and utility (net benefit) as the benefit minus the
harm for the total group, adjusted for the individual patient’s
perception of the trade-off between harm and benefit. Using
this approach, a number of algorithms were compared. The
authors concluded that the ERBP algorithm [13], which the
authors interpret as recommending referral when ‘ESKD risk>
mortality risk provided the patient is not frail’, is not the best at
any level of patient valuation of harm versus benefit. The cur-
rent Kidney Disease: Improving Global Outcomes recommen-
dation [20], to refer those whose 5-year ESKD risk is >50% (1-
year risk >10%), was found to be appropriate only for those
patients whose approach to referral was conservative, i.e. those
who considered the harm:benefit ratio to be <1:1. For those
with a more aggressive approach, referral was said to be benefi-
cial if eGFR was <25mL/min/1.73m2 provided they were
<80 years of age. On a more philosophical level, when looking
at the DCA, all algorithms taking into account the ratio of mor-
tality versus progression risk performed equally well in the ‘av-
erage’ patient (i.e. in the preference range of 2:3–3:2).
The interpretation of the authors that the ERBP algorithm
recommends referral if ‘ESKD risk > mortality risk provided
the patient is not frail’ is an oversimplification not fully consis-
tent with the spirit of the guideline. In fact, referral is recom-
mended for all patients whose risk of ESKD is high provided
that their mortality risk is not very much higher than their
ESKD risk or they are frail, since for these latter patients, man-
agement recommendations might focus on a supportive/pallia-
tive approach. Following the authors’ interpretation of the
algorithm, many patients would be referred whose predicted
mortality risk only moderately exceeds their ESKD risk. In these
circumstances, the shared decision-making process, which re-
ferral would trigger, would encompass both the option of
preparation for RRT and the option of pursuing a conservative
pathway. As mentioned, Hallan et al. [17] could not take into
account the conservative management option, as they lacked
the data to do so.
The recommendation that referral may be beneficial for
patients <80 years of age when their eGFR is <25mL/min/
1.75m2, regardless of the rate of progression, may also pose
problems. As already alluded to, the rate of progression of CKD
tends to be slow in older patients [7–10] and the mortality rate
high [10]. The authors have themselves demonstrated that very
few patients with this level of renal function progress to ESKD,
so most patients would be referred inappropriately. Preparation
for ESKD in these patients would entail fistula formation,
though the proportion of unnecessary procedures in older
patients with this level of renal function has been shown to be
high [21]. In these circumstances, referral without reference to
the trajectory of renal functional decline would seem inappro-
priate [22, 23].
The discussion above highlights the complexity of the deci-
sion-making pathway in older patients with advanced CKD.
The core purpose of this pathway is to integrate patient prefer-
ences with an honest appraisal of the available evidence relating
to viable treatment options, in a process of shared decision
making. Hallan et al. [17] have provided evidence that the two
equations deployed in the ERBP algorithm are fit for the pur-
pose in this context. They also clearly illustrate the impact of pa-
tient preference on decision making. Other approaches may
emerge; for instance, Grams et al. [24] have produced a risk pre-
diction tool for patients with a GFR <30mL/min/1.73m2 that
takes account of the competing risks, the outputs of which in-
clude 2- and 4-year probabilities of the requirement for RRT,
non-fatal cardiovascular events and death. Other models have
emphasized the predictive utility of the surprise question [25]
and impaired nutritional status [26] in this setting. We need to
know much more about how to gain an understanding of an
individual’s perception of, and response to, risk [27] and how
best to communicate risk in conversations with patients [28].
These are crucial issues and central to effective shared decision
making that is at the core of the ERBP algorithm.
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